Assessing AI for Detecting Lung Nodules and Cancer: Pre- and Post-Deployment Study

NCT ID: NCT06746324

Last Updated: 2025-09-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Study Classification

OBSERVATIONAL

Study Start Date

2025-05-15

Study Completion Date

2026-06-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study evaluates the impact of qXR-LN compared to standard radiologist-only interpretations before and after AI deployment. The goal is to compare how well lung nodules and cancers are detected in two time periods: before and after the implementation of the AI tool in routine clinical practice. The study aims to determine whether the AI system can help radiologists identify more actionable lung nodules and diagnose lung cancer earlier, ultimately improving patient outcomes.

No changes will be made to patients' standard care, and all treatment decisions will be based on the clinical judgment of physicians. The study includes patients over 35 years old who undergo chest X-rays for various medical reasons, excluding those with known lung cancer.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study evaluates the clinical impact of the FDA-cleared artificial intelligence (AI) tool, qXR-LN, for detecting lung nodules and diagnosing lung cancer using chest X-rays (CXR). The study employs an ambispective observational cohort design with two cohorts: pre-deployment (before AI implementation) and post-deployment (after AI implementation).

The primary objective is to assess differences in lung nodule detection rates and the percentage of lung cancers diagnosed through the nodule pathway between the two cohorts. Secondary objectives include evaluating whether the AI tool aids in detecting more early-stage lung cancers and identifying reasons for patients dropping out of the nodule clinic pathway.

In the post-deployment cohort, qXR-LN integrates seamlessly with the hospital's existing systems to provide real-time AI findings on radiologists' workstations. Radiologists can accept or reject AI suggestions, ensuring that the final decisions remain under human supervision. Data from both cohorts, including patient demographics, nodule detection rates, cancer diagnoses, and treatment outcomes, will be collected and analyzed.

The study excludes patients under 35 years old and those with known lung cancer at the time of imaging. Ethical considerations include obtaining waivers of consent where applicable and ensuring minimal risk to participants. The findings of this study aim to inform clinical practices and enhance the use of AI tools in lung cancer screening and diagnosis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Nodules Lung Cancers Early-Stage Lung Cancer Artificial Intelligence in Radiology Computer-Aided Detection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pre-Deployment Cohort

Patients undergoing standard chest X-rays prior to the introduction of the AI-based Computer Aided Detection (CAD) system. This cohort represents the baseline population used for comparison, with no AI intervention applied during their imaging or reporting process.

No interventions assigned to this group

Post-Deployment Cohort

Patients undergoing chest X-rays after the AI-based Computer Aided Detection (CAD) tool has been integrated into the clinical workflow. Although not assigned as an "intervention group" per a traditional trial protocol, these patients receive imaging evaluated by the AI tool, and the impact on diagnostic outcomes will be compared to the pre-deployment cohort.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥35 years at the time of chest X-ray acquisition
* Chest X-ray must be obtained as part of routine care (e.g., ordered for respiratory complaints, screening, or other clinical indications)
* Chest X-ray performed using CR/DR/DX imaging modality
* Examination described as "Chest"
* View: PA or AP
* Patient positioned as Erect or Supine
* Image available in valid DICOM format with proper DICOM prefix values (including "DICM" in the header)

Exclusion Criteria

* Patients aged \<35 years at the time of chest X-ray
* Patients with known lung cancer at the time of chest X-ray acquisition
* Lateral views or any imaging modality other than CR/DR/DX
* Imaging or anatomy not specified as Chest (e.g., different body parts or modalities)
Minimum Eligible Age

35 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Florida

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

qXR-LN-UFL-001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

AI Determine Malignancy of GGO on Chest CT
NCT06282068 ENROLLING_BY_INVITATION